Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARE: Infliximab and Antimetabolite Withdrawal Strategies in Crohn's Disease
NCT02177071Phase 4Completed
- Sponsor
- GETAID
- Start
- Oct 2015
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of infliximab, azathioprine, mercaptopurine and methotrexate in Crohn's disease (3 arms), sponsored by GETAID. Primary endpoints: Clinical Relapse Rate at 2 years and Mean Remission Duration at 2 years. Started Oct 2015; status: completed.
02
Drugs
infliximabazathioprinemercaptopurinemethotrexate
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02177071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177071.